

















  





















































<!DOCTYPE html>
<html xmlns="https://www.w3.org/1999/xhtml" lang='en'>
<head>  
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="content-type" content="text/html; charset=UTF-8" />
    <meta name="referrer" content="origin-when-cross-origin"/>
  <title>A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors - Full Text View - ClinicalTrials.gov</title>
    <link href="/ct2/show/NCT02847637" rel="canonical"/>
    
  <!-- Twitter Card data -->
  <meta name="twitter:card" content="summary">
  <meta name="twitter:image" content="https://clinicaltrials.gov/ct2/html/images/ct.gov-nlm-nih-square-logo.png?v1">

  <!-- Open Graph data -->
  <meta property="og:type" content="article" />
  <meta property="og:title" content="A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors - Full Text View - ClinicalTrials.gov">
  <meta property="og:image" content="https://clinicaltrials.gov/ct2/html/images/ct.gov-nlm-nih-square-logo.png?v1">
    <meta property="og:description" content="A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors - Full Text View.">
  <meta property="og:url" content="https://clinicaltrials.gov/ct2/show/NCT02847637">
    
  <link rel="shortcut icon" href="/ct2/html/images/favicon.ico" />
  <link rel='apple-touch-icon-precomposed' href='/ct2/html/images/apple-touch-icon-144x144.png' sizes='144x144'>
  <link rel='apple-touch-icon-precomposed' href='/ct2/html/images/apple-touch-icon-114x114.png' sizes='114x114'>
  <link rel='apple-touch-icon-precomposed' href='/ct2/html/images/apple-touch-icon-72x72.png'   sizes='72x72'>
  <link rel='apple-touch-icon-precomposed' href='/ct2/html/images/apple-touch-icon-precomposed.png' >
  <link rel='apple-touch-icon-precomposed' href='/ct2/html/images/apple-touch-icon.png' >

  <link rel="stylesheet" type="text/css" href="/ct2/html/jquery/css/superfish.css?v=44" media="screen" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/jquery/css/superfish-vertical.css?v=44" media="screen" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/css/glossary.css?v=44" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/css/base.css?v=44" />
  <link rel="stylesheet" type="text/css" href="/ct2/html/css/print.css?v=44" media="print" />
  <link rel="stylesheet" href="/ct2/html/css/w3-ct.css?v=44" type="text/css" />
  <!--[if lt IE 9]>
	<link rel="stylesheet" href="/ct2/html/css/w3-ct-oldIE.css?v=44" type="text/css" />
  <![endif]-->
   	
  <link rel="preconnect" href="https://use.fontawesome.com">
  <link rel="preconnect" href="https://www.ncbi.nlm.nih.gov">
  
  <script src="https://use.fontawesome.com/20a31629ec.js"></script>
<!--[if lte IE 7]>
       <link href="/ct2/html/css/target-IE7-and-below.css" rel="stylesheet" type="text/css">
<![endif]-->

<style type="text/css">
  h2 
  {
      background-color: #EAEAEA;
  }
</style>
<link href="/ct2/html/css/trial-record.css?v=44" rel="stylesheet" type="text/css" />

	<script type="text/javascript" src="/ct2/html/jquery/js/jquery.min.js?v=44"></script><noscript></noscript>
<script type="text/javascript" async src="/ct2/html/jquery/js/superclick.min.js?v=44"></script><noscript></noscript>
<script type="text/javascript" async src="/ct2/html/js/ct.js?v=44"></script><noscript></noscript>
<script type="text/javascript" async src="/ct2/html/js/ctmenu.js?v=44"></script><noscript></noscript>
<script>
var theURL = "/ct2/show/NCT02847637"+window.location.hash;
history.replaceState(null,null,theURL);
</script>

  <meta name="ncbi_sid" content="4ec8b7bc0e309146_36c1a9SID"/>
  <meta name="ncbi_app" content="ctgov"/>
  <meta name="ncbi_db" content="ctgov"/>
  <meta name="ncbi_pdid" content="show_study"/>
  <meta name="ncbi_pcid" content="NCT02847637"/>
  <meta name="ncbi_ctreqid" content="R990F27Q"/>
  <meta name="ncbi_ctsessid" content="S990Dl4A"/>
  <meta name="ncbi_ctipid" content="IZ45kPwP"/>
  <meta name="ncbi_cthost" content="w12"/>
</head>


<body> 
<script type="text/javascript">
    jQuery.getScript("https://www.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
      galert(['#alert_banner', 'body &gt; *:nth-child(1)'])});
</script>

<div id="alert_banner"></div>

<!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET-->
<script type='text/javascript'>
(function(){var g=function(e,h,f,g){
this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null};
this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "};
this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0};
this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g+ "&t=" + (new Date()).getTime();document.body&&document.body.appendChild(a)}};
this.start=function(){var a=this;window.addEventListener?window.addEventListener("load",function(){a.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){a.go()})}};
try{(new g(100,"r","QSI_S_ZN_7WHWRcRMBs9xWYd","https://zn7whwrcrmbs9xwyd-nlmenterprise.siteintercept.qualtrics.com/WRSiteInterceptEngine/?Q_ZID=ZN_7WHWRcRMBs9xWYd")).start()}catch(i){}})();
</script><div id='ZN_7WHWRcRMBs9xWYd'><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div>
<!--END WEBSITE FEEDBACK SNIPPET-->
<div id="glossary" class="glossary"
    aria-describedby="glossary-result" aria-hidden="true">
  <button
      title="Close glossary"
      class="js-glossary-close button button--close js-glossary-toggle usa-button-unstyled"
    ><span class="usa-sr-only">Hide glossary</span>
    <i class="fa fa-times" aria-hidden="true"></i>
  </button>
  <h4 class="glossary-heading">Glossary</h4>
  <p>
  Study record managers: refer to the <a href="https://clinicaltrials.gov/ct2/manage-recs/resources#DataElement"><span style="text-decoration:underline">Data Element Definitions</span></a> if submitting registration or results information.
  </p>
  <p>
  <label for="glossary-search" class="label">Search for terms</label>
  </p>
  <span class="clearable-input">
  <input id="glossary-search" class="js-glossary-search">
   <span data-clear-input="" class="js-glossary-clear button js-glossary-toggle usa-button-unstyled">x</span>
  </span>
  <div class="glossary__content" id="glossary-result">
    <ul class="js-glossary-list"></ul>
  </div>
</div>

<div id="skip"> <a href="#main-content">Skip to Main Content</a> </div>


<script type="text/javascript" src="/ct2/html/js/working.js"></script><noscript></noscript>
<div id="workingDim" class="ct-dim">
  <div id="workingIndicator" class="ct-workingBox" style="text-align:center;vertical-align:middle;">
    <img alt="Working&#8230;" src="/ct2/html/images/working.gif" height="50" >
  </div>
</div>

<div id="wrapper"> 
<div class="ct-inner_wrapper">   			<a href="/ct2/home" style='float:left;border-bottom-width:0;min-width:200px;width:29%;'><img src='/ct2/html/images/ct.gov-nlm-nih-logo.png' alt='ClinicalTrials.gov'/></a>

				<div id="hamburger" class="w3-hide-medium w3-hide-large" style="float:right;border-width:0;display:block;margin-left:1em;padding:4px;"
			title="Show menus">
			<img src="/ct2/html/images/hamburgerMenuIcon.png" alt="ClinicalTrials.gov Menu" style="max-width:30px;cursor:pointer;" 
			 onclick="$('#global-nav-popupMenu').toggle();"/>
		</div>
		<div id="global-nav-popupMenu" class="w3-hide-medium w3-hide-large w3-modal w3-center" 
			 style="display:none;" onclick="$('#global-nav-popupMenu').hide();"> 			<div id="global-nav-popupMenu-content" class="w3-modal-content">
				<div class="w3-container">
				    <span onclick="$('#global-nav-popupMenu').hide();"
				      class="w3-closebtn">&times;</span>
					<ul class="sf-menu sf-vertical">
									<li class="first"><a href="/ct2/search/index">Find Studies<img src="/ct2/html/images/pulldown.png" alt="Find Studies Menu"></a>
			<ul>
                      <li                  ><a                  href="/ct2/home">New Search</a></li>
                      <li                  ><a         href="/ct2/search/advanced">Advanced Search</a></li>
                      <li                  ><a     href="/ct2/search/browse?brwse=cond_cat">See Studies by Topic</a></li>
                      <li                  ><a             href="/ct2/search/map">See Studies on Map</a></li>
                      <li class="new-group"><a           href="/ct2/help/how-find/index">How to Search</a></li>
                      <li                  ><a href="/ct2/help/how-use-search-results">How to Use Search Results</a></li>
                      <li                  ><a        href="/ct2/help/how-find/find-study-results">How to Find Results of Studies</a></li>
                      <li                  ><a          href="/ct2/help/how-read-study">How to Read a Study Record</a></li>
			</ul>
			</li>
			<li><a href="/ct2/about-studies">About Studies<img src="/ct2/html/images/pulldown.png" alt="About Studies Menu"></a>
			<ul>
                      <li><a href="/ct2/about-studies/learn">Learn About Studies</a></li>
                      <li><a  href="/ct2/about-studies/other-sites">Other Sites About Studies</a></li>
                      <li><a         href="/ct2/about-studies/glossary">Glossary of Common Site Terms</a></li>
			</ul>
			</li>
			<li><a href="/ct2/manage-recs">Submit Studies<img src="/ct2/html/images/pulldown.png" alt="Submit Studies Menu"></a>
			<ul>
                      <li><a                          href="/ct2/manage-recs/submit-study">Submit Studies to ClinicalTrials.gov PRS</a></li>
                      <li><a                          href="/ct2/manage-recs/background">Why Should I Register and Submit Results?</a></li>
                      <li><a                                href="/ct2/manage-recs/fdaaa">FDAAA 801 and the Final Rule</a></li>
                      <li class="new-group"><a    href="/ct2/manage-recs/how-apply">How to Apply for a PRS Account</a></li>
                      <li><a                        href="/ct2/manage-recs/how-register">How to Register Your Study</a></li>
                      <li><a                         href="/ct2/manage-recs/how-edit">How to Edit Your Study Record</a></li>
                      <li><a                   href="/ct2/manage-recs/how-report">How to Submit Your Results</a></li>
                      <li class="new-group"><a       href="/ct2/manage-recs/faq">Frequently Asked Questions</a></li>
                      <li                  ><a href="/ct2/manage-recs/resources">Support Materials</a></li>
                      <li                  ><a      href="/ct2/manage-recs/present">Training Materials</a></li>
			</ul>
			</li>
			<li><a href="/ct2/resources">Resources<img src="/ct2/html/images/pulldown.png" alt="Resources Menu"></a>
			<ul>
                      <li                  ><a    href="/ct2/resources/pubs">Selected Publications</a></li>
                      <li                  ><a       href="/ct2/resources/alert">Clinical Alerts and Advisories</a></li>
                      <li                  ><a     href="/ct2/resources/rss">RSS Feeds</a></li>
                      <li class="new-group"><a href="/ct2/resources/trends">Trends, Charts, and Maps</a></li>
                      <li                  ><a   href="/ct2/resources/download">Downloading Content for Analysis</a></li>
			</ul>
			</li>
			<li class="last"><a href="/ct2/about-site">About Site<img src="/ct2/html/images/pulldown.png" alt="About Site Menu"></a>
			<ul>
                      <li class="new-group"><a href="/ct2/about-site/new">What's New</a></li>
                      <li                  ><a    href="/ct2/about-site/background">ClinicalTrials.gov Background</a></li>
                      <li                  ><a    href="/ct2/about-site/results">About the Results Database</a></li>
                      <li                  ><a    href="/ct2/about-site/history">History, Policies, and Laws</a></li>
                      <li                  ><a    href="/ct2/about-site/modernization">ClinicalTrials.gov Modernization</a></li>
                      <li                  ><a   href="/ct2/about-site/for-media">Media/Press Resources</a></li>
                      <li class="new-group"><a          href="/ct2/about-site/link-to">Linking to This Site</a></li>
                      <li                  ><a           href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
                      <li                  ><a      href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			</ul>
			</li>
			<li><a title="Login to the ClinicalTrials.gov Protocol Registration and Results System (PRS)"
				href="/ct2/manage-recs/register"><span style="border-bottom:1px solid;padding-bottom:1px;padding-right:0;">PRS Login</span></a>
			</li>
								</ul>
				</div>
    		</div>
  		</div>		
		
<div 
style="float:right;margin-top:1.5%;" 
class="w3-hide-small">
	<ul class="sf-menu sf-vertical">
				<li class="first"><a href="/ct2/search/index">Find Studies<img src="/ct2/html/images/pulldown.png" alt="Find Studies Menu"></a>
			<ul>
                      <li                  ><a                  href="/ct2/home">New Search</a></li>
                      <li                  ><a         href="/ct2/search/advanced">Advanced Search</a></li>
                      <li                  ><a     href="/ct2/search/browse?brwse=cond_cat">See Studies by Topic</a></li>
                      <li                  ><a             href="/ct2/search/map">See Studies on Map</a></li>
                      <li class="new-group"><a           href="/ct2/help/how-find/index">How to Search</a></li>
                      <li                  ><a href="/ct2/help/how-use-search-results">How to Use Search Results</a></li>
                      <li                  ><a        href="/ct2/help/how-find/find-study-results">How to Find Results of Studies</a></li>
                      <li                  ><a          href="/ct2/help/how-read-study">How to Read a Study Record</a></li>
			</ul>
			</li>
			<li><a href="/ct2/about-studies">About Studies<img src="/ct2/html/images/pulldown.png" alt="About Studies Menu"></a>
			<ul>
                      <li><a href="/ct2/about-studies/learn">Learn About Studies</a></li>
                      <li><a  href="/ct2/about-studies/other-sites">Other Sites About Studies</a></li>
                      <li><a         href="/ct2/about-studies/glossary">Glossary of Common Site Terms</a></li>
			</ul>
			</li>
			<li><a href="/ct2/manage-recs">Submit Studies<img src="/ct2/html/images/pulldown.png" alt="Submit Studies Menu"></a>
			<ul>
                      <li><a                          href="/ct2/manage-recs/submit-study">Submit Studies to ClinicalTrials.gov PRS</a></li>
                      <li><a                          href="/ct2/manage-recs/background">Why Should I Register and Submit Results?</a></li>
                      <li><a                                href="/ct2/manage-recs/fdaaa">FDAAA 801 and the Final Rule</a></li>
                      <li class="new-group"><a    href="/ct2/manage-recs/how-apply">How to Apply for a PRS Account</a></li>
                      <li><a                        href="/ct2/manage-recs/how-register">How to Register Your Study</a></li>
                      <li><a                         href="/ct2/manage-recs/how-edit">How to Edit Your Study Record</a></li>
                      <li><a                   href="/ct2/manage-recs/how-report">How to Submit Your Results</a></li>
                      <li class="new-group"><a       href="/ct2/manage-recs/faq">Frequently Asked Questions</a></li>
                      <li                  ><a href="/ct2/manage-recs/resources">Support Materials</a></li>
                      <li                  ><a      href="/ct2/manage-recs/present">Training Materials</a></li>
			</ul>
			</li>
			<li><a href="/ct2/resources">Resources<img src="/ct2/html/images/pulldown.png" alt="Resources Menu"></a>
			<ul>
                      <li                  ><a    href="/ct2/resources/pubs">Selected Publications</a></li>
                      <li                  ><a       href="/ct2/resources/alert">Clinical Alerts and Advisories</a></li>
                      <li                  ><a     href="/ct2/resources/rss">RSS Feeds</a></li>
                      <li class="new-group"><a href="/ct2/resources/trends">Trends, Charts, and Maps</a></li>
                      <li                  ><a   href="/ct2/resources/download">Downloading Content for Analysis</a></li>
			</ul>
			</li>
			<li class="last"><a href="/ct2/about-site">About Site<img src="/ct2/html/images/pulldown.png" alt="About Site Menu"></a>
			<ul>
                      <li class="new-group"><a href="/ct2/about-site/new">What's New</a></li>
                      <li                  ><a    href="/ct2/about-site/background">ClinicalTrials.gov Background</a></li>
                      <li                  ><a    href="/ct2/about-site/results">About the Results Database</a></li>
                      <li                  ><a    href="/ct2/about-site/history">History, Policies, and Laws</a></li>
                      <li                  ><a    href="/ct2/about-site/modernization">ClinicalTrials.gov Modernization</a></li>
                      <li                  ><a   href="/ct2/about-site/for-media">Media/Press Resources</a></li>
                      <li class="new-group"><a          href="/ct2/about-site/link-to">Linking to This Site</a></li>
                      <li                  ><a           href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
                      <li                  ><a      href="/ct2/about-site/disclaimer">Disclaimer</a></li>
			</ul>
			</li>
			<li><a title="Login to the ClinicalTrials.gov Protocol Registration and Results System (PRS)"
				href="/ct2/manage-recs/register"><span style="border-bottom:1px solid;padding-bottom:1px;padding-right:0;">PRS Login</span></a>
			</li>
				</ul>
    <div style="clear:both;"></div>
</div>
<div style="clear:both;"></div>

</div> 
<div class="ct-outer_breadcrumb w3-container">
	<div id="breadcrumb">
    <ul class="ct-horz-list w3-left">
			<li><a href="/ct2/home">Home</a></li>
												<li><a href="/ct2/results">Search Results</a></li>
										<li>Study Record Detail</li>
    </ul>
    <div id="savedStudies" class="w3-right">
  	<div id="cart" style="cursor:pointer;" onclick="location.href=('/ct2/results'+cartToURL()); showWorking();">
  	<button class="ct-savedStudiesEnabled" id="open-cart-link" type="button" 
  		onclick="location.href=('/ct2/results'+cartToURL()); showWorking();"
  		title="Show previously saved studies.">Saved Studies</button>
  	</div>
</div>
<script type="text/javascript" src="/ct2/html/js/cart.js?v=44"></script><noscript></noscript>

		<script type="text/javascript">
	$(document).ready(function(){
		$("input#saved").prop( 'checked', (inCart("NCT02847637")>=0));
	});
</script>
		<div class="w3-right" style="margin-right: 1em;">
			<label for="saved" title="Add or Remove this study in the Saved Studies list"><input type="checkbox" id="saved" name="NCT02847637" onchange="updateCart('NCT02847637');" style="margin-left:1em;"> Save this study </label>
		</div>
		<div id="maxSavedStudies-popup" class="w3-modal" style="cursor:pointer;border:2px groove" onclick="$('#maxSavedStudies-popup').hide();">
	<div id="maxSavedStudies-popup-content" class="w3-modal-content">
		<div class="w3-display-container" style="border:1px solid #ccc;background-color:#eee;">
			<form>
			<div class="w3-center" style="font-size:large;font-weight:bold;padding:3ex 1.5em;">
				<img src="/ct2/html/images/warning.png" alt="Maximum Saved Studies Reached" style="max-width:1.0rem;cursor:pointer;"/>
			    <b>Warning</b>
				<div style="margin-top:1ex;margin-bottom:0.5ex;">You have reached the maximum number of saved studies (100).</div>
				<div>Please remove one or more studies before adding more.</div>
			</div>
		
			<div class="w3-center" style="padding-bottom:1.5ex">
			  <input class="ct-searchButton" type="button" style="opacity:1.0;font-weight:bold;font-size:inherit;padding:1.1ex 1em;" onclick="$('#maxSavedStudies-popup').hide();" value="Close" title="Close this dialog"/>
			</div>
			</form>
		</div>
	</div>
</div>

	</div>
</div>

<div style="clear:both;"></div>

<div id="main-content" tabindex='-1'>
	
	
		<div class="tr-indent2">
        	<h1 class="tr-h1 ct-sans-serif tr-solo_record">A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors (HAVEN 3)</h1>

  <div class="w3-row">
    <div class="w3-col m6">       <div class="usa-alert usa-alert-warning" style="clear:both;margin:2ex 2em;">
        <table>
          <tr>
            <td style="width:5%">
              <img src="/ct2/html/images/warning.png" style="width:1.3em;" alt=""/>
            </td>
            <td style="padding-right:2em;">
              The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
                            Read our <a href="/ct2/about-site/disclaimer">disclaimer</a> for details.
            </td>
          </tr>
        </table>
      </div>      </div> 
<!--
  <div style="float:right;margin-right:4em">ClinicalTrials.gov Identifier: NCT02847637</div>
-->
  <div class="w3-col m1">&nbsp;</div> 
  <div class="w3-col m5">   <table style="width:95%">
  <tr><td>ClinicalTrials.gov Identifier: NCT02847637</td>
  </tr>
  <tr><td>
      
       
              <div  class="tr-status tr-not-recruiting-colors" >
                        <span style="display:inline;" class="term" data-term="Recruitment Status" title="Show definition">Recruitment Status <i class="fa fa-info-circle term" aria-hidden="true" data-term="Recruitment Status" style="border-bottom-style:none;"></i></span> : 
                    Active, not recruiting
                  
                
  <div style="font-size:inherit">
  <span style="display:inline;" class="term" data-term="First Posted" title="Show definition">First Posted <i class="fa fa-info-circle term" aria-hidden="true" data-term="First Posted" style="border-bottom-style:none;"></i></span> : July 28, 2016</div>
      <div style="font-size:inherit">
    <span style="display:inline;" class="term" data-term="Results First Posted" title="Show definition">Results First Posted <i class="fa fa-info-circle term" aria-hidden="true" data-term="Results First Posted" style="border-bottom-style:none;"></i></span> : November 14, 2018</div>
    <div style="font-size:inherit">
  <span style="display:inline;" class="term" data-term="Last Update Posted" title="Show definition">Last Update Posted <i class="fa fa-info-circle term" aria-hidden="true" data-term="Last Update Posted" style="border-bottom-style:none;"></i></span> : October 1, 2020</div>

  
      </div>
  </td>
  </tr>
  </table>
  </div>
  </div>


                <div class="tr-info-title">Sponsor:</div>
                <div class="tr-info-text" id="sponsor"> Hoffmann-La Roche </div>
                <div class="tr-info-title">Collaborator:</div>
                                  				  				                                    <div class="tr-info-text" id="sponsor1">Chugai Pharmaceutical</div> 
                  				  
                              <div class="tr-info-title">Information provided by (Responsible Party):</div>
                <div class="tr-info-text" id="responsibleparty">Hoffmann-La Roche</div>
              	</div>
<br>


<div id="tabs">
    <ul id="tab-links">
		<li id="full-text"  class="current">Study Details     </li>
		<li id="tabular"   ><a href="/ct2/show/record/NCT02847637" >Tabular View</a></li>
  					<li id="results"   ><a href="/ct2/show/results/NCT02847637">Study Results</a></li>
						<li id="disclaimer"><a title="Disclaimer - opens new window"  href="/ct2/about-site/disclaimer" onclick="openNewWindow('/ct2/about-site/disclaimer'); return false"
>Disclaimer</a></li>
		<li id="howtoread"><a title="How to Read a Study Record - opens new window"  href="/ct2/help/how-read-study" onclick="openNewWindow('/ct2/help/how-read-study'); return false"
>How to Read a Study Record</a></li>
    </ul>
</div>  <!--
<div style="background-color:#f6f6f6;margin-top:5.0ex;padding-bottom:1.5ex;"> </div>
-->
		
	<div id="tab-body">
		<div class="tr-indent2" style="background-color:white;">
						  
<!-- purpose_section -->
<div class="tr-indent1" style="margin-top:1ex">

<div class="tr-subsection">
	<div class="ct-header2"><a id="studydesc"></a>Study Description</div>
	<div class="tr-underline"></div>
	<div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
</div>

<div class="tr-indent2" style="margin-top:2ex">

  <div class="ct-body3">Brief Summary:</div>
  <div class="ct-body3 tr-indent2">This is a randomized, global, multicenter, open-label, Phase 3 clinical study in participants with severe hemophilia A without inhibitors against Factor VIII (FVIII) who are 12 years or older. The study evaluates two prophylactic emicizumab regimens versus no prophylaxis in this population with emphasis on efficacy, safety, and pharmacokinetics.</div><br/>

    <!-- condition, intervention, phase summary table -->
  <table class="ct-data_table tr-data_table" border="1" style="margin:auto;width:80%;">
    <tr style="text-align:left;">
            <th class="ct-header3 tr-pale_banner_color">
<span style="display:inline;" class="term" data-term="Condition/disease" title="Show definition">Condition or disease <i class="fa fa-info-circle term" aria-hidden="true" data-term="Condition/disease" style="border-bottom-style:none;"></i></span>       </th>
                  <th class="ct-header3 tr-pale_banner_color">
<span style="display:inline;" class="term" data-term="Intervention/treatment" title="Show definition">Intervention/treatment <i class="fa fa-info-circle term" aria-hidden="true" data-term="Intervention/treatment" style="border-bottom-style:none;"></i></span>       </th>
                  <th class="ct-header3 tr-pale_banner_color">
<span style="display:inline;" class="term" data-term="Phase" title="Show definition">Phase <i class="fa fa-info-circle term" aria-hidden="true" data-term="Phase" style="border-bottom-style:none;"></i></span>       </th>
          </tr>
    <tr style="text-align:left;vertical-align:top;">
            <td class="ct-body3">
                <span style="display:block;margin-bottom:1ex;">Hemophilia A</span>
              </td>
                  <td class="ct-body3">
                <span style="display:block;margin-bottom:1ex;">Drug: Emicizumab</span>
              </td>
                  <td class="ct-body3" style="white-space:nowrap;">
                <span style="display:block;margin-bottom:1ex;">Phase 3</span>
              </td>
          </tr>
  </table>
  <br/>
  
  
  </div> 
<div class="tr-subsection">
  <div class="ct-header2"><a id="studydesign"></a>Study Design</div>
  <div class="tr-underline"></div>
  <div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
</div>

  <p>
  <table class="ct-layout_table tr-tableStyle tr-studyInfo" style="margin-bottom:2ex;">
   <caption>Layout table for study information</caption>
   <thead>
    <tr>
      <th id="studyInfoColTitle"></th>
      <th id="studyInfoColData"></th>
    </tr>
    </thead>
    <tbody>
        <tr>
      <td headers="studyInfoColTitle">
<span style="display:inline;" class="term" data-term="Study Type" title="Show definition">Study Type <i class="fa fa-info-circle term" aria-hidden="true" data-term="Study Type" style="border-bottom-style:none;"></i></span> :</td>
      <td headers="studyInfoColData" style="padding-left:1em">
        Interventional
                &nbsp;(Clinical Trial)
                
        
      </td>
    </tr>
                    <tr>
      <td headers="studyInfoColTitle">Actual
<span style="display:inline;" class="term" data-term="Enrollment" title="Show definition">Enrollment <i class="fa fa-info-circle term" aria-hidden="true" data-term="Enrollment" style="border-bottom-style:none;"></i></span> :</td>
      <td headers="studyInfoColData" style="padding-left:1em">152 participants</td>
    </tr>
                <tr>
            <td headers="studyInfoColTitle">Allocation:</td>
            <td headers="studyInfoColData" style="padding-left:1em">Randomized</td>
    </tr>
        <tr>
            <td headers="studyInfoColTitle">Intervention Model:</td>
            <td headers="studyInfoColData" style="padding-left:1em">Parallel Assignment</td>
    </tr>
        <tr>
            <td headers="studyInfoColTitle">Masking:</td>
            <td headers="studyInfoColData" style="padding-left:1em"> None (Open Label)</td>
    </tr>
        <tr>
            <td headers="studyInfoColTitle">Primary Purpose:</td>
            <td headers="studyInfoColData" style="padding-left:1em"> Treatment</td>
    </tr>
                    <tr>
<!--
      <td headers="studyInfoColTitle" style="padding-top:2ex;">Official Title:</td>
-->
      <td headers="studyInfoColTitle">Official Title:</td>
      <td headers="studyInfoColData" style="padding-left:1em;">A Randomized, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Patients Without Inhibitors</td>
    </tr>
    
            <tr>
        <td headers="studyInfoColTitle">  Actual <span style="display:inline;" class="term" data-term="Study Start Date" title="Show definition">Study Start Date <i class="fa fa-info-circle term" aria-hidden="true" data-term="Study Start Date" style="border-bottom-style:none;"></i></span> :</td>
        <td headers="studyInfoColData" style="padding-left:1em">September 27, 2016</td>
      </tr>
                  <tr>
        <td headers="studyInfoColTitle">  Actual <span style="display:inline;" class="term" data-term="Primary Completion Date" title="Show definition">Primary Completion Date <i class="fa fa-info-circle term" aria-hidden="true" data-term="Primary Completion Date" style="border-bottom-style:none;"></i></span> :</td>
        <td headers="studyInfoColData" style="padding-left:1em">September 15, 2017</td>
      </tr>
                  <tr>
        <td headers="studyInfoColTitle">  Estimated <span style="display:inline;" class="term" data-term="Study Completion Date" title="Show definition">Study Completion Date <i class="fa fa-info-circle term" aria-hidden="true" data-term="Study Completion Date" style="border-bottom-style:none;"></i></span> :</td>
        <td headers="studyInfoColData" style="padding-left:1em">May 10, 2022</td>
      </tr>
            </tbody>
    </table>

    <!-- NLM links -->
<p>
<div class="tr-indent2">
  <div class="usa-alert usa-alert-warning nlm-info">
    <strong>Resource links provided by the National Library of Medicine</strong>
    <img src="/ct2/html/images/NIH_NLM_ABRV_BLK_4.png" style="width:5em; float:right;" alt=""/>
    <p>
    <p>

    <!-- ghr links -->
  <div style="margin-bottom:2ex">
    <a class="tr-study-link" href="https://medlineplus.gov/genetics/" title="MedlinePlus Genetics" onclick="openNewWindow('https://medlineplus.gov/genetics/'); return false">MedlinePlus Genetics</a> related topics:
    	    	    	<a class="tr-study-link" style="margin-left:0.5em;" href="https://medlineplus.gov/genetics/condition/hemophilia" title="Hemophilia at Genetics Home Reference" onclick="openNewWindow('https://medlineplus.gov/genetics/condition/hemophilia'); return false">Hemophilia</a>
	          </div>
  
    <!-- medline links -->
  <div style="margin-bottom:2ex;">
    <a class="tr-study-link" href="https://medlineplus.gov/" title="MedlinePlus" onclick="openNewWindow('https://medlineplus.gov/'); return false">MedlinePlus</a> related topics:
    	    	    	<a class="tr-study-link" style="margin-left:0.5em;" href="https://medlineplus.gov/hemophilia.html" title="Hemophilia at MedlinePlus" onclick="openNewWindow('https://medlineplus.gov/hemophilia.html'); return false">Hemophilia</a>
	          </div>
  
    <!-- SIS links -->
  <div style="margin-bottom:2ex;">
    <a class="tr-study-link" href="https://druginfo.nlm.nih.gov/drugportal" title="Drug Information Portal" onclick="openNewWindow('https://druginfo.nlm.nih.gov/drugportal'); return false">Drug Information</a> available for:
    	    	    	<a class="tr-study-link" style="margin-left:0.5em;" href="https://druginfo.nlm.nih.gov/drugportal/name/Emicizumab" title="Emicizumab at Drug Information Portal" onclick="openNewWindow('https://druginfo.nlm.nih.gov/drugportal/name/Emicizumab'); return false">Emicizumab</a>
	          </div>
  
    <!-- ORD links -->
  <div style="margin-bottom:2ex;">
    <a class="tr-study-link" href="https://rarediseases.info.nih.gov/gard" title="Genetic and Rare Diseases Information Center" onclick="openNewWindow('https://rarediseases.info.nih.gov/gard'); return false">Genetic and Rare Diseases Information Center</a> resources:
    	    	    	<a class="tr-study-link" style="margin-left:0.5em;" href="https://rarediseases.info.nih.gov/diseases/10418/hemophilia" title="Hemophilia at Genetic and Rare Diseases Information Center" onclick="openNewWindow('https://rarediseases.info.nih.gov/diseases/10418/hemophilia'); return false">Hemophilia</a>
	        	    	    	<a class="tr-study-link" style="margin-left:0.5em;" href="https://rarediseases.info.nih.gov/diseases/6591/hemophilia-a" title="Hemophilia&#160;A at Genetic and Rare Diseases Information Center" onclick="openNewWindow('https://rarediseases.info.nih.gov/diseases/6591/hemophilia-a'); return false">Hemophilia&#160;A</a>
	          </div>
  
  
  <!-- Ropr Link -->
<!-- Commented out RoPR
  -->

  <div style="margin-bottom:2ex;">
  <a class="tr-study-link" href="/ct2/info/fdalinks" title="Show FDA resources page" onclick="openNewWindow('/ct2/info/fdalinks'); return false">U.S. FDA Resources</a>
  </div>

  </div>
</div>


  
  <br/>
    </div>

    <!-- arms and groups table -->
    		<div class="tr-subsection">
		    		    	<div class="ct-header2"><a id="armgroup"></a>Arms and Interventions</div>
		    		    <div class="tr-underline"></div>
			<div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
		</div>
	
    <div style="padding-left:.8em; padding-right:1.2em;text-align:left;">
        <p>
    <table class="ct-data_table tr-data_table" style="padding:5px;width:100%;border-width:1px;">
      <thead>
      <tr style="text-align:left;">
        <th class="ct-header3 tr-pale_banner_color" style="width:50%;">
            				<span style="display:inline;" class="term" data-term="Arm" title="Show definition">Arm <i class="fa fa-info-circle term" aria-hidden="true" data-term="Arm" style="border-bottom-style:none;"></i></span> 			        </th>
                <th class="ct-header3 tr-pale_banner_color">
			<span style="display:inline;" class="term" data-term="Intervention/treatment" title="Show definition">Intervention/treatment <i class="fa fa-info-circle term" aria-hidden="true" data-term="Intervention/treatment" style="border-bottom-style:none;"></i></span>         </th>
              </tr>
      </thead>
      <tbody>
            <tr style="text-align:left;vertical-align:top;">
        <td class="ct-body3">
          Experimental: A: Emicizumab 1.5 mg/kg/week
<div class="tr-indent2" style="margin-top:0.5ex">Participants who received episodic treatment with FVIII prior to study entry will receive emicizumab prophylaxis at a dose of 3 milligrams per kilogram per week (mg/kg/week) subcutaneously for 4 weeks, followed by 1.5 mg/kg/week emicizumab subcutaneously until the end of study (maximum up to 6 years).</div>
        </td>
                <td class="ct-body3">
                      Drug: Emicizumab
<div class="tr-indent2" style="margin-top:0.5ex">Participants will receive emicizumab prophylaxis at the specified dose subcutaneously. Upon implementation of protocol version 4, treatment duration will be extended. During this study prolongation, each participant may choose a preferred emicizumab dosing regimen among those permitted and continue on that dosing regimen until discontinuation from the study (up to 6 years).</div>
<div class="tr-indent2" style="margin-top:0.5ex">Other Names:<ul style="margin-top:0.5ex">
<li>Hemlibra</li>
<li>RO5534262</li>
<li>ACE910</li>
</ul>
</div><br/>
                  </td>
              </tr>
            <tr style="text-align:left;vertical-align:top;">
        <td class="ct-body3">
          Experimental: B: Emicizumab 3 mg/kg/2 weeks
<div class="tr-indent2" style="margin-top:0.5ex">Participants who received episodic treatment with FVIII prior to study entry will receive emicizumab prophylaxis at a dose of 3 mg/kg/week subcutaneously for 4 weeks, followed by 3 mg/kg/2 weeks emicizumab subcutaneously until the end of study (maximum up to 6 years).</div>
        </td>
                <td class="ct-body3">
                      Drug: Emicizumab
<div class="tr-indent2" style="margin-top:0.5ex">Participants will receive emicizumab prophylaxis at the specified dose subcutaneously. Upon implementation of protocol version 4, treatment duration will be extended. During this study prolongation, each participant may choose a preferred emicizumab dosing regimen among those permitted and continue on that dosing regimen until discontinuation from the study (up to 6 years).</div>
<div class="tr-indent2" style="margin-top:0.5ex">Other Names:<ul style="margin-top:0.5ex">
<li>Hemlibra</li>
<li>RO5534262</li>
<li>ACE910</li>
</ul>
</div><br/>
                  </td>
              </tr>
            <tr style="text-align:left;vertical-align:top;">
        <td class="ct-body3">
          Active Comparator: C: No Prophylaxis
<div class="tr-indent2" style="margin-top:0.5ex">Participants who received episodic treatment with FVIII prior to study entry will be randomized to continue episodic FVIII treatment when they start the trial; they will have the opportunity to switch to emicizumab prophylaxis after 24 weeks on-study.</div>
        </td>
                <td class="ct-body3">
                      Drug: Emicizumab
<div class="tr-indent2" style="margin-top:0.5ex">Participants will receive emicizumab prophylaxis at the specified dose subcutaneously. Upon implementation of protocol version 4, treatment duration will be extended. During this study prolongation, each participant may choose a preferred emicizumab dosing regimen among those permitted and continue on that dosing regimen until discontinuation from the study (up to 6 years).</div>
<div class="tr-indent2" style="margin-top:0.5ex">Other Names:<ul style="margin-top:0.5ex">
<li>Hemlibra</li>
<li>RO5534262</li>
<li>ACE910</li>
</ul>
</div><br/>
                  </td>
              </tr>
            <tr style="text-align:left;vertical-align:top;">
        <td class="ct-body3">
          Experimental: D: Emicizumab 1.5 mg/kg/week (Pre-study FVIII Prophylaxis)
<div class="tr-indent2" style="margin-top:0.5ex">Participants who received FVIII prophylaxis prior to study entry will receive emicizumab prophylaxis at a dose of 3 mg/kg/week subcutaneously for 4 weeks, followed by 1.5 mg/kg/week emicizumab subcutaneously until the end of study (maximum up to 6 years).</div>
        </td>
                <td class="ct-body3">
                      Drug: Emicizumab
<div class="tr-indent2" style="margin-top:0.5ex">Participants will receive emicizumab prophylaxis at the specified dose subcutaneously. Upon implementation of protocol version 4, treatment duration will be extended. During this study prolongation, each participant may choose a preferred emicizumab dosing regimen among those permitted and continue on that dosing regimen until discontinuation from the study (up to 6 years).</div>
<div class="tr-indent2" style="margin-top:0.5ex">Other Names:<ul style="margin-top:0.5ex">
<li>Hemlibra</li>
<li>RO5534262</li>
<li>ACE910</li>
</ul>
</div><br/>
                  </td>
              </tr>
            </tbody>
    </table>
          </div>
    <br/>

    
    <!-- more details -->
  <br/>
  <div class="tr-subsection">
	  <div class="ct-header2"><a id="outcomemeasures"></a>Outcome Measures</div>
	  <div class="tr-underline"></div>
	  <div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
  </div>
  <br/>
  <div class="tr-indent3" style="margin-right:1em;">

        <!-- primary outcomes -->
    <div class="ct-body3">
<span style="display:inline;" class="term" data-term="Primary Outcome Measure" title="Show definition">Primary Outcome Measures <i class="fa fa-info-circle term" aria-hidden="true" data-term="Primary Outcome Measure" style="border-bottom-style:none;"></i></span> :
      <ol style="margin-top:1ex; margin-bottom:1ex;">
            	<li style="margin-top:0.7ex;">Annualized Bleeding Rate (ABR) for Treated Bleeds [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to at least 24 weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was assessed using a negative binomial (NB) regression model, which accounts for different follow-up times, with the number of bleeds as a function of randomization and the time that each participant stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes the number of bleeds (&lt;9 or &#8805;9) in the last 24 weeks prior to study entry as a stratification factor. A bleed is considered a &quot;treated bleed&quot; if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a &quot;treatment for bleed&quot;, irrespective of the time between treatment and the preceding bleed. Bleeds due to surgery/procedure are excluded.</div><br/>
            </ol>
    </div>
    <br/>
    
        <!-- secondary outcomes -->
    <div class="ct-body3"  style="margin-right:1em;">
<span style="display:inline;" class="term" data-term="Secondary Outcome Measure" title="Show definition">Secondary Outcome Measures <i class="fa fa-info-circle term" aria-hidden="true" data-term="Secondary Outcome Measure" style="border-bottom-style:none;"></i></span> :
      <ol style="margin-top:1ex; margin-bottom:1ex;">
            <li style="margin-top:0.7ex;">Annualized Bleeding Rate (ABR) for All Bleeds [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to at least 24 weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of all bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was assessed using a NB regression model, which accounts for different follow-up times, with the patient's number of bleeds as a function of randomization and the time that each patient stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes the number of bleeds (&lt;9 or &#8805;9) in the last 24 weeks prior to study entry as a stratification factor. &quot;All bleeds&quot; comprises both treated and non-treated bleeds. In this definition, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded.</div><br/>
            <li style="margin-top:0.7ex;">Annualized Bleeding Rate (ABR) for Treated Joint Bleeds [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to at least 24 weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated joint bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was assessed using a NB regression model, which accounts for different follow-up times, with the patient's number of bleeds as a function of randomization and the time that each patient stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes the number of bleeds (&lt;9 or &#8805;9) in the last 24 weeks prior to study entry as a stratification factor. A &quot;joint bleed&quot; is defined as a bleed reported as &quot;joint&quot; and with at least one of the following symptoms: increasing swelling or warmth of the skin over the joint; and/or increasing pain, decreased range of motion, or difficulty using the joint compared with baseline. It is considered a &quot;treated joint bleed&quot; if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a &quot;treatment for bleed&quot;. Bleeds due to surgery/procedure are excluded.</div><br/>
            <li style="margin-top:0.7ex;">Annualized Bleeding Rate (ABR) for Treated Spontaneous Bleeds [&nbsp;Time&nbsp;Frame:&nbsp;From baseline to at least 24 weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated spontaneous bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was assessed using a NB regression model, which accounts for different follow-up times, with the patient's number of bleeds as a function of randomization and the time that each patient stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes the number of bleeds (&lt;9 or &#8805;9) in the last 24 weeks prior to study entry as a stratification factor. A bleed is classified as &quot;spontaneous&quot; if there is no other known contributing factor such as trauma or procedure/surgery. A &quot;treated spontaneous bleed&quot; is a spontaneous bleed that is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a &quot;treatment for bleed&quot;. Bleeds due to surgery/procedure are excluded.</div><br/>
            <li style="margin-top:0.7ex;">Annualized Bleeding Rate (ABR) for Treated Target Joint Bleeds [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline to at least 24 weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The number of treated target joint bleeds over the efficacy period is presented as an annualized bleeding rate (ABR) that was assessed using a NB regression model, which accounts for different follow-up times, with the patient's number of bleeds as a function of randomization and the time that each patient stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes the number of bleeds (&lt;9 or &#8805;9) in the last 24 weeks prior to study entry as a stratification factor. A &quot;target joint bleed&quot; is defined as a bleed reported as a joint bleed into a target joint, defined as at least 3 bleeds into the same joint during the last 24 weeks prior to study entry. It is considered a &quot;treated target joint bleed&quot; if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a &quot;treatment for bleed&quot;. Bleeds due to surgery/procedure are excluded.</div><br/>
            <li style="margin-top:0.7ex;">Intra-Participant Comparison of ABR for Treated Bleeds on Study Versus Pre-Study in Participants From the Non-Interventional Study Population Previously Treated With Factor VIII (FVIII) Prophylaxis (NISP) [&nbsp;Time&nbsp;Frame:&nbsp;24 weeks prior to study entry, Baseline, through at least 24 weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">This is an intra-participant comparison of the annualized bleeding rate (ABR) for treated bleeds on study versus pre-study in the NIS population previously treated with FVIII prophylaxis in NIS BH29768. The number of treated bleeds over the efficacy period is presented as an ABR that was assessed using a NB regression model, which accounts for different follow-up times, with the number of bleeds as a function of treatment and the time that each participant stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes a repeated statement to account for intra-participant comparison. A bleed is considered a &quot;treated bleed&quot; if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a &quot;treatment for bleed&quot;, irrespective of the time between treatment and the preceding bleed. Bleeds due to surgery/procedure are excluded.</div><br/>
            <li style="margin-top:0.7ex;">Intra-Participant Comparison of ABR for All Bleeds on Study Versus Pre-Study in Participants From the Non-Interventional Study Population Previously Treated With FVIII Prophylaxis (NISP) [&nbsp;Time&nbsp;Frame:&nbsp;24 weeks prior to study entry, Baseline, through at least 24 weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">This is an intra-participant comparison of the annualized bleeding rate (ABR) for all bleeds on study versus pre-study in the NIS population previously treated with FVIII prophylaxis in NIS BH29768. The number of all bleeds over the efficacy period is presented as an ABR that was assessed using a NB regression model, which accounts for different follow-up times, with the participant's number of bleeds as a function of treatment and the time that each participant stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes a repeated statement to account for intra-participant comparison. &quot;All bleeds&quot; comprises both treated and non-treated bleeds. In this definition, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded.</div><br/>
            <li style="margin-top:0.7ex;">Intra-Participant Comparison of ABR for Treated Bleeds on Study Versus Pre-Study in Participants From the NIS Population Previously Treated With Episodic FVIII (NISE) [&nbsp;Time&nbsp;Frame:&nbsp;24 weeks prior to study entry, Baseline, through at least 24 weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">This is an intra-participant comparison of the annualized bleeding rate (ABR) for treated bleeds on study versus pre-study in the NIS population previously treated with episodic FVIII in NIS BH29768. The number of treated bleeds over the efficacy period is presented as an ABR that was assessed using a NB regression model, which accounts for different follow-up times, with the number of bleeds as a function of treatment and the time that each participant stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes a repeated statement to account for intra-participant comparison. A bleed is considered a &quot;treated bleed&quot; if it is directly followed (i.e., no intervening bleed) by a hemophilia medication reported to be a &quot;treatment for bleed&quot;, irrespective of the time between treatment and the preceding bleed. Bleeds due to surgery/procedure are excluded.</div><br/>
            <li style="margin-top:0.7ex;">Intra-Participant Comparison of ABR for All Bleeds on Study Versus Pre-Study in Participants From the NIS Population Previously Treated With Episodic FVIII (NISE) [&nbsp;Time&nbsp;Frame:&nbsp;24 weeks prior to study entry, Baseline, through at least 24 weeks&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">This is an intra-participant comparison of the annualized bleeding rate (ABR) for all bleeds on study versus pre-study in the NIS population previously treated with episodic FVIII in NIS BH29768. The number of all bleeds over the efficacy period is presented as an ABR that was assessed using a NB regression model, which accounts for different follow-up times, with the participant's number of bleeds as a function of treatment and the time that each participant stays in the study (i.e., length of the efficacy period) included as an offset in the model. The model also includes a repeated statement to account for intra-participant comparison. &quot;All bleeds&quot; comprises both treated and non-treated bleeds. In this definition, all bleeds are included, irrespective of treatment with coagulation factors, with the following exception: bleeds due to surgery/procedure are excluded.</div><br/>
            <li style="margin-top:0.7ex;">Hemophilia A Quality of Life (Haem-A-QoL) Questionnaire Physical Health Subscore for Adult Participants (&#8805;18 Years of Age) in the Randomized Population at Week 25 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 25&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The Haem-A-QoL questionnaire has been developed and used in hemophilia A participants, assessing very specific aspects of dealing with hemophilia. The questionnaire consists of items pertaining to 10 domains: physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feeling, relationships, treatment, view of yourself, and outlook for the future. The total score for each domain ranges from 0 to 100 with lower scores reflective of better quality of life. Physical Health domain score is reported (range 0 to 100, with lower scores reflective of better physical health). The means were derived via an analysis of covariance (ANCOVA) model and have been adjusted for the following co-variates: baseline score, treatment group, and treatment by baseline interaction term.</div><br/>
            <li style="margin-top:0.7ex;">Haem-A-QoL Questionnaire Total Score for Adult Participants (&#8805;18 Years of Age) in the Randomized Population at Week 25 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 25&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The Haem-A-QoL questionnaire has been developed and used in hemophilia A participants, assessing very specific aspects of dealing with hemophilia. The questionnaire consists of items pertaining to 10 domains: physical health, sports and leisure, school and work, dealing with hemophilia, family planning, feeling, relationships, treatment, view of yourself, and outlook for the future. The total score for each domain ranges from 0 to 100 with lower scores reflective of better quality of life. Haem-A-QoL Total Score is the average of all domain scores and it ranges from 0 to 100, with lower scores reflective of better quality of life. The means were derived via an analysis of covariance (ANCOVA) model and have been adjusted for the following co-variates: baseline score, treatment group, and treatment by baseline interaction term.</div><br/>
            <li style="margin-top:0.7ex;">European Quality of Life 5-Dimensions-5 Levels (EQ-5D-5L) Questionnaire Visual Analogue Scale (VAS) Score in the Randomized Population at Week 25 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 25&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L VAS. The VAS is designed to rate the participant's current health state on a scale from 0 to 100, where 0 represents the worst imaginable health state and 100 represents the best imaginable health state. The means were derived via an analysis of covariance (ANCOVA) model and have been adjusted for the following co-variates: baseline score, treatment group, and treatment by baseline interaction term.</div><br/>
            <li style="margin-top:0.7ex;">EQ-5D-5L Questionnaire Index Utility Score in the Randomized Population at Week 25 [&nbsp;Time&nbsp;Frame:&nbsp;Baseline, Week 25&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">EQ-5D-5L is a standardized, participant-rated questionnaire to assess health-related quality of life. The EQ-5D-5L includes 2 components: the EQ-5D-5L health state profile (descriptive system) and the EQ-5D-5L VAS. The EQ-5D-5L health state profile is designed to record the participant's current health state in 5 domains: mobility, selfcare, usual activities, pain/discomfort, and anxiety/depression. Responses from the five domains are used to calculate a single index utility score on a scale of 0 to 1, with higher scores reflective of better quality of life. The means were derived via an analysis of covariance (ANCOVA) model and have been adjusted for the following co-variates: baseline score, treatment group, and treatment by baseline interaction term.</div><br/>
            <li style="margin-top:0.7ex;">Hemophilia-Specific Quality of Life - Short Form (Haemo-QoL-SF) Questionnaire Score in Adolescent Participants (12 to 17 Years of Age) in the Randomized Population at Week 25 [&nbsp;Time&nbsp;Frame:&nbsp;Week 25&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The Haemo-QoL-SF contains 35 items, which cover nine domains considered relevant for the children's health-related quality of life (physical health, feelings, view of yourself, family, friends, other people, sports and school, dealing with hemophilia and treatment). Items are rated with five respective response options: never, seldom, sometimes, often, and always. Haemo-QoL-SF total score range from 0 to 100, where lower scores reflect better health-related quality of life.</div><br/>
            <li style="margin-top:0.7ex;">Percentage of Participants With at Least One Adverse Event [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks after last dose of study drug (up to 2.5 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The percentage of participants experiencing at least one adverse event, including all non-serious and serious adverse events, is reported here. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of approximately 1 year.</div><br/>
            <li style="margin-top:0.7ex;">Percentage of Participants With Grade &#8805;3 Adverse Events [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks after last dose of study drug (up to 2.5 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The World Health Organization (WHO) toxicity grading scale will be used for assessing adverse event severity. For adverse events that are not specifically listed in the WHO toxicity grading scale, a grade 3 adverse event is defined as: severe, marked limitation in activity, some assistance usually required, medical intervention or therapy required, hospitalization possible; and a grade 4 adverse event is defined as: life-threatening, extreme limitation in activity, significant assistance required, significant medical intervention or therapy required, hospitalization or hospice care probable. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of approximately 1 year.</div><br/>
            <li style="margin-top:0.7ex;">Percentage of Participants With Adverse Events Leading to Withdrawal From Treatment [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks after last dose of study drug (up to 2.5 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of approximately 1 year.</div><br/>
            <li style="margin-top:0.7ex;">Percentage of Participants With Adverse Events of Changes From Baseline in Vital Signs [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks after last dose of study drug (up to 2.5 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The percentage of participants with adverse events of changes from baseline in vital signs is reported here. Vital signs measurements consisted of heart and respiratory rate, temperature, and systolic and diastolic blood pressures, with an abnormal vital sign value being outside of the normal range. An abnormal vital sign result is reported as an adverse event if it meets any of the following criteria: is accompanied by clinical symptoms; results in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); results in a medical intervention or a change in concomitant therapy; or is clinically significant in the investigator's judgment. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of approximately 1 year.</div><br/>
            <li style="margin-top:0.7ex;">Percentage of Participants With Adverse Events of Changes From Baseline in Physical Examination Findings [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks after last dose of study drug (up to 2.5 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">Post-baseline physical examination abnormalities that were not present at baseline or worsened were reported as adverse events. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of approximately 1 year.</div><br/>
            <li style="margin-top:0.7ex;">Percentage of Participants With Adverse Events of Abnormal Laboratory Values [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks after last dose of study drug (up to 2.5 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">The percentage of participants with adverse events of abnormal laboratory values is reported here. An abnormal laboratory value is defined as a laboratory test result outside of the normal range for hematology or serum chemistries. It is reported as an adverse event if it meets any of the following criteria: is accompanied by clinical symptoms; results in a change in study treatment (e.g., dosage modification, treatment interruption or discontinuation); results in a medical intervention or a change in concomitant therapy; or is clinically significant in the investigator's judgment. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of approximately 1 year.</div><br/>
            <li style="margin-top:0.7ex;">Percentage of Participants With Local Injection-Site Reactions [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks after last dose of study drug (up to 2.5 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">Local adverse events that occurred within 24 hours after study drug administration and, in the investigator's opinion, were judged to be related to study drug injection, were captured as an &quot;injection-site reaction&quot; on the Adverse Event electronic Case Report Form (eCRF). An injection-related reaction that was localized was marked as a &quot;local injection-site reaction.&quot; At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of approximately 1 year.</div><br/>
            <li style="margin-top:0.7ex;">Percentage of Participants With Thromboembolic Events [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks after last dose of study drug (up to 2.5 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of approximately 1 year.</div><br/>
            <li style="margin-top:0.7ex;">Percentage of Participants With Thrombotic Microangiopathy [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks after last dose of study drug (up to 2.5 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of approximately 1 year.</div><br/>
            <li style="margin-top:0.7ex;">Percentage of Participants With Systemic Hypersensitivity, Anaphylaxis, or Anaphylactoid Reactions [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks after last dose of study drug (up to 2.5 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of approximately 1 year.</div><br/>
            <li style="margin-top:0.7ex;">Percentage of Participants With Anti-Emicizumab Antibodies [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks after last dose of study drug (up to 2.5 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">A validated ELISA method was used to analyze the levels of anti-emicizumab antibodies in plasma. A sample was considered positive for anti-emicizumab antibodies if the test result reached or exceeded a pre-determined threshold. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of approximately 1 year.</div><br/>
            <li style="margin-top:0.7ex;">Percentage of Participants With De Novo Development of Factor VIII (FVIII) Inhibitors [&nbsp;Time&nbsp;Frame:&nbsp;From Baseline up to 24 weeks after last dose of study drug (up to 2.5 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">Levels of anti-FVIII antibodies (inhibitors) were analyzed using a validated FVIII activity assay. A participant was considered to have developed de novo FVIII inhibitors if the inhibitor levels detected in a post-baseline sample reached or exceeded a pre-determined threshold. At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of approximately 1 year.</div><br/>
            <li style="margin-top:0.7ex;">Trough Plasma Concentration (Ctrough) of Emicizumab [&nbsp;Time&nbsp;Frame:&nbsp;Predose (Hour 0) on every week during Weeks 1-4, every 2 weeks during Weeks 5-8, every 4 weeks during Weeks 9-24, every 8 weeks during Weeks 25-48, every 12 weeks thereafter up to the end of the study (up to 2 years)&nbsp;]<div class="tr-indent2" style="margin-top:1ex;">Plasma concentrations of emicizumab were analyzed using a validated Enzyme Linked Immunosorbent Assay (ELISA). The lower limit of quantitation was 0.1 micrograms per milliliter (&#956;g/mL). At the clinical cut-off date for primary analysis (15 Sep 2017), data was collected over a period of approximately 1 year.</div><br/>
            </ol>
    </div>
    <br/>
    
    
    
  </div>
  
			  
<!-- eligibility_section -->
<div class="tr-indent1" style="margin-top:3ex; border:1px solid white">
<div class="tr-subsection">
	<div class="ct-header2"><a id="eligibility"></a>Eligibility Criteria</div>
	<div class="tr-underline"></div>
	<div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
</div>
<br/>

<p>
  <div class="tr-indent2 usa-alert usa-alert-warning nlm-info">
    <strong>Information from the National Library of Medicine</strong>
    <img src="/ct2/html/images/NIH_NLM_ABRV_BLK_4.png" style="width:5em; float:right;" alt=""/>
    <p>
    <p>
    <em>Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, <a href="/ct2/about-studies/learn" title="Learn About Clinical Studies"><u>Learn About Clinical Studies.</u></a>
    </em>
  </div>


  <br/>
  <div class="tr-indent2">
    <table class="ct-layout_table tr-tableStyle tr-studyInfo">
      <caption>Layout table for eligibility information</caption>
      <thead>
        <tr>
          <th id="elgType"></th>
          <th id="elgData"></th>
        </tr>
      </thead>
      <tbody>
            <tr>
        <td headers="elgType" class="ct-nowrap">Ages Eligible for Study: &nbsp; </td>
        <td headers="elgData" style="padding-left:1em">12 Years and older &nbsp; (Child, Adult, Older Adult)</td>
      </tr>
                  <tr>
        <td headers="elgType" class="ct-nowrap">Sexes Eligible for Study: &nbsp; </td>
        <td headers="elgData" style="padding-left:1em">All</td>
      </tr>
                              <tr>
        <td headers="elgType" class="ct-nowrap">Accepts Healthy Volunteers: &nbsp; </td>
        <td headers="elgData" style="padding-left:1em">No</td>
      </tr>
                  </tbody>
    </table>

    
        <div class="ct-header3" style="margin-top:2ex">Criteria</div>
    <div class="tr-indent2"><p style="margin-top:1ex; margin-bottom:1ex;">Inclusion Criteria:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Body weight &gt;/= 40 kilogram (kg) at the time of screening</li>
    <li style="margin-top:0.7ex;">Diagnosis of severe congenital hemophilia A</li>
    <li style="margin-top:0.7ex;">Documentation of the details of prophylactic or episodic FVIII treatment and of number of bleeding episodes for at least the last 24 weeks</li>
    <li style="margin-top:0.7ex;">Adequate hematologic function</li>
    <li style="margin-top:0.7ex;">Adequate hepatic function</li>
    <li style="margin-top:0.7ex;">Adequate renal function</li>
    <li style="margin-top:0.7ex;">For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of less than (&lt;) 1 percent (%) per year during the treatment period and for at least 5 elimination half-lives (24 weeks) after the last dose of study drug</li>
  </ul>
  <p style="margin-top:0ex; margin-bottom:1ex;">Exclusion Criteria:</p>
  <ul style="margin-top:1ex; margin-bottom:1ex;">
    <li style="margin-top:0.7ex;">Inherited or acquired bleeding disorder other than hemophilia A</li>
    <li style="margin-top:0.7ex;">Previous or current treatment for thromboembolic disease or signs of thromboembolic disease</li>
    <li style="margin-top:0.7ex;">Conditions that may increase risk of bleeding or thrombosis</li>
    <li style="margin-top:0.7ex;">History of clinically significant hypersensitivity associated with monoclonal antibody therapies or components of the emicizumab injection</li>
    <li style="margin-top:0.7ex;">Known human immunodeficiency virus (HIV) infection with cluster of differentiation (CD) 4 count &lt;200 cells per microliter (cells/mcL) within 24 weeks prior to screening. Participants with HIV infection who has CD4 greater than (&gt;) 200 and meet all other criteria are eligible</li>
    <li style="margin-top:0.7ex;">Use of systemic immunomodulators at enrollment or planned use during the study, with the exception of anti-retroviral therapy</li>
    <li style="margin-top:0.7ex;">Participants who are at high risk for thrombotic microangiopathy (TMA) (for example, have a previous medical or family history of TMA), in the investigator's judgment</li>
    <li style="margin-top:0.7ex;">Concurrent disease, treatment, or abnormality in clinical laboratory tests that could interfere with the conduct of the study, may pose additional risk, or would, in the opinion of the investigator, preclude the participant's safe participation in and completion of the study</li>
    <li style="margin-top:0.7ex;">Planned surgery (excluding minor procedures) during the study</li>
    <li style="margin-top:0.7ex;">Receipt of emicizumab in a prior investigational study; an investigational drug to treat or reduce the risk of hemophilic bleeds within 5 half-lives of last drug administration; a non-hemophilia-related investigational drug concurrently, within last 30 days or 5 half-lives, whichever is shorter</li>
    <li style="margin-top:0.7ex;">Pregnant or lactating, or intending to become pregnant during the study</li>
  </ul></div>
    
  </div>

  </div>

			  
<!-- location_section -->
<a id="contacts"></a>
<div class="tr-indent1" style="margin-top:3ex">
<div class="tr-subsection">
	<div class="ct-header2"><a id="contactlocation"></a>Contacts and Locations</div>
	<div class="tr-underline"></div>
	<div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
</div>
<br/>


<div class="tr-indent2" style="margin-top:2ex">

<!--
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. 
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. 
For general information, see <a href="/ct2/about-studies/learn" target="def_win" onClick="openNewWindow('/ct2/about-studies/learn'); return false;" title="Learn About Clinical Studies - opens new window"><u>Learn About Clinical Studies.</u></a>
<br/>
-->

  
  <div class="usa-alert usa-alert-warning nlm-info">
    <strong>Information from the National Library of Medicine</strong>
    <img src="/ct2/html/images/NIH_NLM_ABRV_BLK_4.png" style="width:5em; float:right;" alt=""/>
    <p>
    <p>
    <em>
    To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
    </em>
    <p>
    <em>
    Please refer to this study by its ClinicalTrials.gov identifier (NCT number): <strong>NCT02847637</strong>
    </em>
  </div>
  <br/>

  <!-- contacts -->
  
  <!-- locations -->
   <a id="locn"></a>
  <div class="ct-header3" style="margin-top:2ex;margin-bottom:2ex;">Locations</div>

      <script type="text/javascript" async src="/ct2/html/js/ExpandCollapseScript.js"></script>
    
    <span id="EXPAND_CONTROL-Locations" class="EXPAND tr-showAndHide"       onclick="toggleSectionAndControls('-Locations');document.getElementById('locn').scrollIntoView({behavior: 'smooth', block: 'start'});" 
      title="Show 39 study locations">
      <img src="/ct2/html/images/expand.png" alt="Show">
      <span style="padding-bottom:3px"> Show 39 study locations</span>
    </span>
    <span  id="COLLAPSE_CONTROL-Locations" class="COLLAPSE tr-showAndHide" style="display:none"      onclick="toggleSectionAndControls('-Locations');" 
      title="Hide 39 study locations">
      <img src="/ct2/html/images/collapse.png"  alt="Hide">
      <span style="padding-bottom:3px"> Hide 39 study locations</span>
    </span>
     
  <div id="COLLAPSE-Locations" class="COLLAPSE" style="display:none">
        <div class="tr-table_cover">
      <table class="ct-layout_table tr-indent2">
        <caption>Layout table for location information</caption>
        <thead>
          <tr>
            <th id="locName"></th>
            <th id="locStatus"></th>
          </tr>
        </thead>
        <tbody>
                                    <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, California</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Santa Monica Oncology Center</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Santa Monica, California, United States, 90403  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, District of Columbia</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Georgetown Uni Medical Center; Lombardi Cancer Center</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Washington, District of Columbia, United States, 20007  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, Florida</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">University of Florida</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Gainesville, Florida, United States, 32607  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, Georgia</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Winship Cancer Institute</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Atlanta, Georgia, United States, 30322  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, Massachusetts</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Dana-Farber Cancer Institute; Brigham and Women's Cancer Center</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Boston, Massachusetts, United States, 02115  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, Michigan</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Children's Hospital of Michigan; Pediatrics</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Detroit, Michigan, United States, 48201  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, New York</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Cornell Univ Medical College; Hematology-Oncolog</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">New York, New York, United States, 10021  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United States, Washington</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Bloodworks Northwest (formerly Puget Sound Blood Center); Hemophilia</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Seattle, Washington, United States, 98104  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Australia, South Australia</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Royal Adelaide Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Adelaide, South Australia, Australia, 5000  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Australia, Victoria</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">The Alfred Hospital, Melbourne; Thrombosis and Haemostasis Unit</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Melbourne, Victoria, Australia, 3004  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Australia, Western Australia</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">The Perth Blood Institute</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Nedlands, Western Australia, Australia, 6009  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Costa Rica</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">ICIC</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">San Jose, Costa Rica, 1000  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">France</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Hopital Cardio-vasculaire Louis Pradel; Hemostase clinique</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Bron, France, 69677  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">CH de Bicetre; Centre de Traitement d' Hemophilie</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Le Kremlin Bicetre, France, 94275  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Groupe Hospitalier Necker Enfants Malades</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Paris, France, 75015  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Germany</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Universit&#228;tsklinikum Bonn; Institut f&#252;r Experimentelle H&#228;matologie und Transfusionsmedizin</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Bonn, Germany, 53127  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Ireland</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">St James's Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Dublin, Ireland, 8  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Italy</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">IRCCS Ca' Granda Ospedale Maggiore Policlinico; Centro Emofilia e Trombosi &quot;Angelo Bianchi e Bonomi&quot;</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Milano, Lombardia, Italy, 20122  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">AOU Careggi; SOD Malattie Emorragiche</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Firenze, Toscana, Italy, 50134  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Japan</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Nagoya University Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Aichi, Japan, 466-8560  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">St. Marianna University School of Medicine Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Kanagawa, Japan, 216-8511  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Sendai Medical Center</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Miyagi, Japan, 983-8520  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Nara Medical University Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Nara, Japan, 634-8522  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">NHO Osaka National Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Osaka, Japan, 540-0006  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Tokyo Medical University Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Tokyo, Japan, 160-0023  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Ogikubo Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Tokyo, Japan, 167-0035  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Korea, Republic of</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Severance Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Seoul, Korea, Republic of, 03722  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Poland</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Uniwersyteckie Centrum Kliniczne; Klinika Hematologii i Transplantologii</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Gdansk, Poland, 80-952  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">SPSK Nr1 Klinika Hematoo&amp;Transpl.Szpiku</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Lublin, Poland, 20-081  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">ALVAMED Lekarskie Gabinety Specjalistyczne</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Pozna&#324;, Poland, 61-696  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Instytut Hematologii i Transfuzjologii; Klinika Zaburze&#324; Hemostazy i Chor&#243;b Wewn&#281;trznych</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Warsaw, Poland, 02-776  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">South Africa</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Charlotte Maxeke Johannesburg Hospital; Haemophilia Comprehensive Care Center</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Johannesburg, South Africa, 2193  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Spain</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Hospital Universitario la Paz; Servicio de Hematologia</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Madrid, Spain, 28046  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Hospital Universitario Virgen del Rocio; Servicio de Hematologia</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Sevilla, Spain, 41013  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">Taiwan</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Changhua Christian Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Chang Hua, Taiwan, 500  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Taichung Veterans General Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Taichung, Taiwan, 407  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Taipei Medical University Hospital</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Taipei, Taiwan, 110  </td></tr>
                                                            <tr><td colspan="2" class="ct-header3" style="padding-top:2ex;">United Kingdom</td></tr>
                                      <tr>
                            <td headers="locName" style="padding-left:2em;">Cardiff and Vale NHS Trust</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">Cardiff, United Kingdom, CF14 4XW  </td></tr>
                                                          <tr>
                            <td headers="locName" style="padding-left:2em;">Royal Free Hospital; Haemophilia Centre</td>
                                          <td headers="locStatus"></td>
                          </tr>
                          <tr><td colspan="2" style="padding:0;padding-left:4em;">London, United Kingdom, NW3 2QG  </td></tr>
                                          </tbody>
      </table>
    </div>
  </div>   
  
  <!-- sponsors -->
      <div class="ct-header3" style="margin-top:2ex">Sponsors and Collaborators</div>
              <div class="tr-indent2" style="margin-top:1ex">Hoffmann-La Roche</div>
              <div class="tr-indent2" style="margin-top:1ex">Chugai Pharmaceutical</div>
        
  <!-- overall officials -->
    <div class="ct-header3" style="margin-top:2ex">Investigators</div>
  <div class="tr-table_cover">
  <table class="ct-layout_table tr-indent2">
    <caption>Layout table for investigator information</caption>
    <thead>
    <tr>
      <th id="role" style="visibility:hidden"></th>
      <th id="name" style="visibility:hidden"></th>
      <th id="affiliation" style="visibility:hidden"></th>
      <th id="address" style="visibility:hidden"></th>
    </tr>
    </thead>
        <tr>
      <td headers="role">Study Director:</td>
      <td headers="name">Clinical Trials</td>
            <td headers="affiliation">Hoffmann-La Roche</td>
            <td headers="address"></td>
    </tr>
      </table>
  </div>
  

</div>
</div>
						
<!-- more_info_section -->

<!-- Large docs section -->

    <div class="tr-indent1" style="margin-top:5ex; border:1px solid white">
    <span class="ct-header2">&nbsp; Study Documents (Full-Text)</span>

    <div class="tr-indent2">
      <br/>
      Documents provided by Hoffmann-La Roche:
            <div class="tr-indent2" style="margin-top:2ex">
        <a class="tr-study-link" href="/ProvidedDocs/37/NCT02847637/Prot_000.pdf" title="Study Protocol" onclick="openNewWindow('/ProvidedDocs/37/NCT02847637/Prot_000.pdf'); return false">Study Protocol</a>&nbsp; [PDF] November 30, 2016
      </div>
            <div class="tr-indent2" style="margin-top:2ex">
        <a class="tr-study-link" href="/ProvidedDocs/37/NCT02847637/SAP_001.pdf" title="Statistical Analysis Plan" onclick="openNewWindow('/ProvidedDocs/37/NCT02847637/SAP_001.pdf'); return false">Statistical Analysis Plan</a>&nbsp; [PDF] June 20, 2017
      </div>
                 <br/>
    </div>
  </div>
    

<!-- More info section -->
  <div class="tr-indent1" style="margin-top:3ex; border:1px solid white">
  <div class="tr-subsection">
  	<div class="ct-header2"><a id="moreinfo"></a>More Information</div>
  	<div class="tr-underline"></div>
  	<div class="tr-dropdown" style="padding-right:10em">
Go&nbsp;to&nbsp;
<button class="tr-dropbtn" style="font-weight:bold; font-size:14px">
<img src="/ct2/html/images/pulldown.png" alt="sections">
</button>

  <div class="tr-dropdown-content">
	<a href="#wrapper">Top of Page</a>
    <a href="#studydesc">Study Description</a>
    <a href="#studydesign">Study Design</a>

    <!-- arms and groups table -->
        <a href="#armgroup">Arms and Interventions</a>
    
        <a href="#outcomemeasures">Outcome Measures</a>
        <a href="#eligibility">Eligibility Criteria</a>
    <a href="#contactlocation">Contacts and Locations</a>
    <a href="#moreinfo">More Information</a>
  </div>
</div>
  </div>
  
  <div class="tr-indent2" style="margin-top:1em;">


    <!-- Additional Information -->
    

    <!-- Available Study Data/Document -->
    

  <!-- References -->
    
    
  <!-- Derived References -->
        <span class="ct-header3">Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):</span>
      <div class="tr-indent2">
                <div style="margin-top:2ex">
                    <a href="/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRFtagCwFK45A6h9Ei4L3BUgWwNG0it." title="Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, Schmitt C, Jim&#233;nez-Yuste V, Kempton C, Dhalluin C, Callaghan MU, Bujan W, Shima M, Adamkewicz JI, Asikanius E, Levy GG, Kruse-Jarres R. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018 Aug 30;379(9):811-822. doi: 10.1056/NEJMoa1803550." onclick="openNewWindow('/ct2/bye/rQoPWwoRrXS9-i-wudNgpQDxudhWudNzlXNiZip9Ei7ym67VZRFtagCwFK45A6h9Ei4L3BUgWwNG0it.'); return false">Mahlangu J, Oldenburg J, Paz-Priel I, Negrier C, Niggli M, Mancuso ME, Schmitt C, Jim&#233;nez-Yuste V, Kempton C, Dhalluin C, Callaghan MU, Bujan W, Shima M, Adamkewicz JI, Asikanius E, Levy GG, Kruse-Jarres R. Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med. 2018 Aug 30;379(9):811-822. doi: 10.1056/NEJMoa1803550.</a>
                            </div>
              </div>
      <br/>
    
   
  <table class="ct-layout_table tr-tableStyle tr-moreInfo" style="margin-top:1ex;">
    <caption>Layout table for additonal information</caption>
    <thead>
    <tr>
      <th id="colTitle1"></th>
      <th id="colData1"></th>
    </tr>
    </thead>
    <tbody>
        <tr>
      <td headers="colTitle1" class="ct-nowrap">Responsible Party:</td>
      <td headers="colData1" style="padding-left:1em">Hoffmann-La Roche</td>
    </tr>
        <tr>
      <td headers="colTitle1" class="ct-nowrap">ClinicalTrials.gov Identifier:</td>
      <td headers="colData1" style="padding-left:1em">
        <a class="tr-study-link" title="Current version of study NCT02847637 on ClinicalTrials.gov" href="https://clinicaltrials.gov/show/NCT02847637">NCT02847637</a> &nbsp; &nbsp;

  <script type="text/javascript">
    <!--
    // Scramble access to archive site -
    // don't want crawlers directing users to outdated versions of the study
    // this should be opaque to crawlers that don't execute javascript
    var yyy=new Array(
      ['<','a clas','s="tr-study','-link c', 't-now','rap" t','itle="Hist','orical vers','ions of '],
      ['study ','NCT02847637',' on Clin','icalTrials.','go'],
      ['v Ar','chive',' Sit','e" ','onc','lick="','openN','ewWin', 'dow(','\'/ct2/', 'history/'],
      ['NCT02847637','\'); return', ' false;" '],
      ['href','="/ct2/','history/','NCT02847637"','>'],
      ['Histo','ry of C','hange','s<','/','a>']);
    var i=0;
    var j=0;
    var xxx='';
    for (i=0; i<yyy.length; i++)
      for (j=0; j<yyy[i].length; j++)
        xxx+=yyy[i][j];
    document.write(xxx)
    -->
  </script>

      </td>
    </tr>
            <tr>
      <td headers="colTitle1" class="ct-nowrap">Other Study ID Numbers:</td>
      <td headers="colData1" style="padding-left:1em">
                                    BH30071 <br/>
                                                2016-000072-17 ( EudraCT Number )<br/>
                            </td>
    </tr>
            <tr>
      <td headers="colTitle1" class="ct-nowrap">First Posted:</td>
      <td headers="colData1" style="padding-left:1em">July 28, 2016
          &nbsp;&nbsp;
          <a class="tr-study-link ct-nowrap" href="/ct2/keydates/NCT02847637"
                title="View key record dates for NCT02847637"
                onclick="openNewWindow('/ct2/keydates/NCT02847637'); return false;">Key Record Dates</a>
      </td>
    </tr>
            <tr>
      <td headers="colTitle1" class="ct-nowrap">Results First Posted:</td>
      <td headers="colData1" style="padding-left:1em">November 14, 2018</td>
    </tr>
        <tr>
      <td headers="colTitle1" class="ct-nowrap">Last Update Posted:</td>
      <td headers="colData1" style="padding-left:1em">October 1, 2020
      </td>
    </tr>
        <tr>
      <td headers="colTitle1" class="ct-nowrap">Last Verified:</td>
      <td headers="colData1" style="padding-left:1em">September 2020
      </td>
    </tr>
           
    <!-- Plan to Share Data -->
        </tbody>
  </table>

    <br/>
  <table class="ct-layout_table tr-tableStyle tr-moreInfo" style="margin-top:1ex">
    <caption>Layout table for additional information</caption>
    <thead>
    <tr>
      <th id="colTitle2"></th>
      <th id="colData2"></th>
    </tr>
    </thead>
    <tbody>       
        <tr>
      <td headers="colTitle2" class="ct-nowrap">Studies a U.S. FDA-regulated Drug Product:</td>
      <td headers="colData2" style="padding-left:1em">Yes</td>
    </tr>
            <tr>
      <td headers="colTitle2" class="ct-nowrap">Studies a U.S. FDA-regulated Device Product:</td>
      <td headers="colData2" style="padding-left:1em">No</td>
    </tr>
                    </tbody>
  </table>
  
  
    <!-- keywords -->
        	
    	    	  	<div class="tr-tableLabel">Keywords provided by Hoffmann-La Roche:</div>
    	    	<div class="tr-indent3">
          <table class="ct-layout_table tr-moreInfo" style="width:100%;">
    	      <thead>
    	      <tr>
    	        <th id="keywordCol1" style="width:50%;"></th>
    	        <th id="keywordCol2" style="width:50%;"></th>
    	      </tr>
    	      </thead>
    	      <tr>
    	        <td headers="keywordCol1" style="padding-left:1em;">
    	              	          Hemophilia A<br/>
    	              	          Emicizumab<br/>
    	              	        </td>
    	            	        <td></td>
    	            	      </tr>
    	    </table>
    	</div>
    
    <!-- mesh terms -->
          <div class="tr-tableLabel">Additional relevant MeSH terms:</div>
      <div class="tr-indent3">
        <table class="ct-layout_table tr-meshTerms" style="width:100%;">
          <caption>Layout table for MeSH terms</caption>
          <thead>
          <tr>
            <th id="meshTermCol1" style="width:50%;"></th>
            <th id="meshTermCol2"></th>
          </tr>
          </thead>
          <tr>
            <td headers="meshTermCol1" style="padding-left:1em;">
                            Hemophilia A<br/>
                            Blood Coagulation Disorders, Inherited<br/>
                            Blood Coagulation Disorders<br/>
                            Hematologic Diseases<br/>
                          </td>
                        <td headers="meshTermCol1" style="padding-left:1em;">
                            Coagulation Protein Disorders<br/>
                            Hemorrhagic Disorders<br/>
                            Genetic Diseases, Inborn<br/>
                          </td>
                      </tr>
        </table>
      </div>
    
  <br/>

  <!--
        <span class="ct-body3">ClinicalTrials.gov processed this record on July 02, 2021</span><br/>
      -->
    <br/>  
  </div>
   </div>
						
			<div id="to-top"><a href="#wrapper">To Top</a></div>
			
			<div style="clear:both;"></div>
		</div>
	</div>
</div>  
<div>       <div id="for-footer">
        <ul class="ct-horz-list">
            <li style="border-left:0;"><a    href="/ct2/help/for-patient">For Patients and Families</a></li>
            <li><a href="/ct2/help/for-researcher">For Researchers</a></li>
            <li><a     href="/ct2/help/for-manager">For Study Record Managers</a></li>
        </ul>
    </div>

</div>  
<div id="footer-menu">
    <ul class="ct-horz-list">
		<li><a     href="/ct2/home">Home</a></li>
		<li><a     href="/ct2/resources/rss">RSS Feeds</a></li>
		<li><a     href="/ct2/sitemap">Site Map</a></li>
		<li><a     href="/ct2/about-site/terms-conditions">Terms and Conditions</a></li>
		<li><a     href="/ct2/about-site/disclaimer">Disclaimer</a></li>
		<li><a     href="https://support.nlm.nih.gov/knowledgebase/category/?id=CAT-01242&amp;category=clinicaltrials.gov&amp;hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02847637" onclick="openNewWindow('https://support.nlm.nih.gov/knowledgebase/category/?id=CAT-01242&amp;category=clinicaltrials.gov&amp;hd_url=https%3A%2F%2Fclinicaltrials.gov%2Fct2%2Fshow%2FNCT02847637'); return false">Customer Support</a></li>
	</ul>
</div>

</div>  
<div id="fine-print">
	<ul class="ct-horz-list">
		<li ><a title="NLM copyright information - opens new window"  href="https://www.nlm.nih.gov/copyright.html" onclick="openNewWindow('https://www.nlm.nih.gov/copyright.html'); return false"
>Copyright</a></li>
		<li ><a title="NLM privacy policy - opens new window"  href="https://www.nlm.nih.gov/privacy.html" onclick="openNewWindow('https://www.nlm.nih.gov/privacy.html'); return false"
>Privacy</a></li>
		<li ><a href="/ct2/accessibility" title="NLM Accessibility">Accessibility</a></li>
		<li ><a title="NLM viewers and players - opens new window"  href="https://www.nlm.nih.gov/plugins.html" onclick="openNewWindow('https://www.nlm.nih.gov/plugins.html'); return false"
>Viewers and Players</a></li>
		<li ><a title="NIH Freedom of Information Act office - opens new window"  href="https://www.nih.gov/icd/od/foia/index.htm" onclick="openNewWindow('https://www.nih.gov/icd/od/foia/index.htm'); return false"
>Freedom of Information Act</a></li>
		<li ><a title="USA.gov - opens new window"  href="https://www.usa.gov/" onclick="openNewWindow('https://www.usa.gov/'); return false"
>USA.gov</a></li>
	</ul>
    <ul class="ct-horz-list">
       <li><a title="U.S. National Library of Medicine - opens new window"  href="https://www.nlm.nih.gov/" onclick="openNewWindow('https://www.nlm.nih.gov/'); return false"
>U.S. National Library of Medicine</a></li>
       <li><a title="U.S. National Institutes of Health - opens new window"  href="https://www.nih.gov/" onclick="openNewWindow('https://www.nih.gov/'); return false"
>U.S. National Institutes of Health</a></li>
       <li><a title="U.S. Department of Health and Human Services - opens new window"  href="https://www.hhs.gov/" onclick="openNewWindow('https://www.hhs.gov/'); return false"
>
            U.S. Department of Health and Human Services</a></li>
    </ul>
</div>

<script type="text/javascript">__ncbi_sg_gaMode="clinicaltrials"</script>
<script type="text/javascript" src="/ct2/html/js/instrumentNCBIBaseJS.min.js?v=2"></script><noscript></noscript>
<script type="text/javascript" src="/ct2/html/js/main-glossary.js?v=44"></script><noscript></noscript>
<script type="text/javascript">
//OnSubmit routine - copy over some useful data and submit
function sendSearchPing() {
// Get pinger values
var cVals = ncbi.sg.getInstance()._cachedVals;
var app = cVals['ncbi_app'];
var db = cVals['ncbi_db'];
var pdid = cVals['ncbi_pdid'];
var pcid = cVals['ncbi_pcid'];
// Populate search details
var searchDetails = {};
searchDetails['jsevent'] = 'search';
searchDetails['searchtext'] = jQuery('#header-search-query').val();
if (app!=null) searchDetails['ncbi_app'] = app.value;
if (db!=null) searchDetails['ncbi_db'] = db.value;
if (pdid!=null) searchDetails['ncbi_pdid'] = pdid.value;
if (pcid!=null) searchDetails['ncbi_pcid'] = pcid.value;
// Send ping msg
ncbi.sg.ping(searchDetails);
};
</script>


</body>
</html>
